title: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.
abstract: OBJECTIVE
  To evaluate the therapeutic efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.
  
  
  METHODS
  One hundred and fifty-one patients were randomly assigned to receive either recombinant interferon alpha-2b (nine million units three times per week) and lamivudine (100 mg/daily per os) for 24 weeks or lamivudine alone (100 mg/daily per os) for 52 weeks. Patients were followed up for a further 48 weeks.
  
  
  RESULTS
  Sustained HBeAg seroconversion with undetectable serum levels of HBV DNA was observed in 25 of 76 patients (33%) treated with the combination therapy and in 11 of 75 patients (15%) treated with monotherapy (P=0.014). Histological improvement defined as a reduction of at least two points in the inflammation score as compared with pretreatment score was observed in 35 of 76 patients (46%) treated with combination therapy and in 20 of 75 patients (27%) treated with monotherapy (P=0.021). Both therapeutic regimens were well tolerated.
  
  
  CONCLUSIONS
  Six-month treatment with interferon alpha-2b and lamivudine in combination appeared to increase the rate of sustained HBeAg seroconversion compared to 1-year lamivudine monotherapy. However, the potential benefit of combining lamivudine and interferon should be investigated further in studies with different regimens of combination therapy.
authors.affiliation: Department of Emergency Medicine, University La Sapienza, Rome, Italy. g.barbaro@tin.it
authors.forename: G
authors.initials: G
authors.lastname: Barbaro
authors.forename: F
authors.initials: F
authors.lastname: Zechini
authors.forename: A M
authors.initials: AM
authors.lastname: Pellicelli
authors.forename: R
authors.initials: R
authors.lastname: Francavilla
authors.forename: G
authors.initials: G
authors.lastname: Scotto
authors.forename: D
authors.initials: D
authors.lastname: Bacca
authors.forename: M
authors.initials: M
authors.lastname: Bruno
authors.forename: S
authors.initials: S
authors.lastname: Babudieri
authors.forename: M
authors.initials: M
authors.lastname: Annese
authors.forename: F
authors.initials: F
authors.lastname: Matarazzo
authors.forename: G
authors.initials: G
authors.lastname: Di Stefano
authors.forename: G
authors.initials: G
authors.lastname: Barbarini
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000145:classification / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D019259:Lamivudine / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D000410:Alanine Transaminase